Jean-Luc Coll
  • E-mail :[email]
  • Phone : +33 6 37 77 54 58
  • Location : Grenoble, France
Last update 2021-12-23 19:29:54.216

Jean-Luc Coll Ph. D. Genetics, Immunology and Differentiation

Course and current status

Present position:

Director of Research INSERM-UGA U1209, CNRS UMR5309, Institute for Advanced Biosciences, Grenoble, France 

Head of the Team “CANCER TARGETS AND EXPERIMENTAL THERAPEUTICS”, www.iab.univ-grenoble-alpes.fr

Other:

Président de la Commission Nationale 4 de la Fondation ARC– Membre du Conseil scientifique

President of the French Society of Nanomedicine (SFNano, www.sfnano.fr)

Invited position: Extraordinary Professor, University of PretoriaSouth Africa


Formation :

Ph.D. degree in Genetics, Immunology and Differentiation, C. Bernard University of Lyon, 1992

Habilitation à Diriger des Recherches Université Grenoble Alpes, 1999


Scientific summary

I earned my Ph.D. degree in “Differentiation, Genetic and Immunology” at the University of Lyon. My research interest was focused on the study of the external-pH regulation of several genes in Escherichia coli.

I then moved to the Burnham Institute in La Jolla (San-Diego, USA), to study the role of vinculin, an adhesion protein. I knocked-out this gene and demonstrated the role of vinculin in cell adhesion and cancer progression.

I came back to France in 1994 to continue working on cancer in the Centre de lutte contre le cancer Léon Bérard in Lyon. During 4 years, I started a gene therapy program, using non-viral delivery systems like cationic lipids and polymers (PEI).

Since 1999, I moved to Grenoble where, as Director of Research at INSERM (Institut National de la Santé et de la Recherche Médicale) I am in charge of the team “Cancer Targets and Experimental Therapeutics” in the Institute for Advanced Biosciences in Grenoble.

Since the last 20 years, I have been working at the interfaces between biology, chemistry, physics and medicine with a clinical (veterinary and human) and industrial (2 Start-up) vision. Our main focused in the team is the development of theranostic approaches against cancer based on nanomedicine and innovative irradiation approaches (Near-infrared light, Xrays and neutrons).

Image d’exemple